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Chapter 1: Introduction 
 The number of infants born with symptoms of withdrawal related to passive drug 
exposure in-utero has been steadily increasing in the United States.  In 2012, approximately one 
infant was born every hour with signs of drug withdrawal as a result of maternal opioid use 
(Patrick, et al., 2012). Maternal use of opioids may cause neonatal withdrawal or acute toxicity 
that may lead to long-term neurodevelopmental effects. Intrauterine exposure to opioids causes 
symptoms of withdrawal in 55 to 94 percent of infants. This pattern of withdrawal is universally 
known as Neonatal Abstinence Syndrome (Newman, 2014). 
Neonatal Abstinence Syndrome (NAS) is a constellation of clinical findings associated 
with drug withdrawal in neonates exposed to drugs in-utero, most commonly opioids (Backes, et 
al., 2011). In 1975, a syndrome of opiate withdrawal in newborns was first described by 
Finnegan et al (Hudak & Tan, 2012).  The syndrome is characterized by dysregulation of central, 
autonomic, and gastrointestinal functioning. Central nervous system symptoms include an 
excessive high pitched cry, poor sleep quality following feedings, increased muscle tone, 
tremors, and convulsions. Autonomic dysregulation symptoms exhibited include increased 
sweating, yawning and sneezing, and increased respirations. Gastrointestinal signs including 
excessive sucking, poor feeding, regurgitation or vomiting and loose stools are also common 
(Logan, Brown, & Hayes, 2013). 
The use of both licit and illicit drugs can lead to a substantial burden on the health of a 
society. The epidemic of opioid use in the United States has resulted in increased numbers of 
maternal opioid dependence resulting in neonatal withdrawal syndrome; ICD-9 code 779.5 
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(Hudak & Tan, 2012).  Between 2000 and 2009, the incidence of NAS tripled with over 13,000 
babies diagnosed with the condition in 2009 (Ordean & Chisamore, 2014). 
Description of the Problem 
 Use of opioid pain relievers in the United States is higher than any other nation, with 
prescribing rates for opioids twice as high as the second ranking nation, Canada. The state of 
Tennessee has been ranked as the second highest in the United States, following Alabama, for 
prescribing rates for opioid pain relievers.(Paulozzi, Mack, & Hockenberry, 2014).  Illicit drug 
use is prevalent in 16.2% of pregnant teens and 7.4% in pregnant women aged 18-25 years.  The 
rate of maternal opiate use has increased nearly 5-fold in the last decade (Patrick, et al., 2012). 
Maternal reporting of illicit drug use is most likely lower when self-reporting when compared to 
results of biologic screening, leading to underestimated actual rates of intrauterine drug exposure 
(Hudak & Tan, 2012). 
 The financial burdens of NAS on society are considerable.  The cost in the neonatal 
intensive care unit (NICU) for an infant with NAS is an average of $3,500 per day, with an 
average length of stay of 30 days. In 2009, 77.6% of infants with NAS were covered by state 
Medicaid programs (Patrick, et al., 2012).  Public health and medical costs related to the care of 
infants diagnosed with NAS in 2009 was estimated between $70.6 million and $112.6 million in 
the United States (Jones, et al., 2010).   
 The quality of care the mother receives during pregnancy can greatly affect the outcome 
of the infant exposed to drugs in-utero (Jensen, 2014).  The substance-using woman is at risk for 
complications due to the exposure affecting not only her own health and wellbeing, but the 
passive exposure of her developing fetus as well (Paltrow & Flavin, 2013). This high-risk 
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population may fail to attend regular gynecologic appointments or obtain prenatal care due to 
fears related to substance abuse revelation, resulting in possible punitive action including loss of 
child custody (Murphy-Oikonen, Montelpare, Bertoldo, Southon, & Persichino, 2012).  In a 
drastic move to control the epidemic the state of Tennessee passed the controversial Pregnancy 
Criminalization Law, SB1391 on May 16, 2014 (Tn.gov, 2014). This legislative action stipulates 
that a woman can be prosecuted for assault charges due to the illegal use of a narcotic drug while 
pregnant if her child is born addicted to or harmed by the narcotic drug (DuBois, 2014).  
Rationale for Review 
Evidence found in the literature review reflects factors related to this growing epidemic 
and public health concern of NAS, but there is limited data that evaluates the role of the Family 
Nurse Practitioner specifically. The rationale for this review of literature is to examine the 
etiology, pathophysiology, clinical manifestations, tools of assessment, management, and 
strategies for the prevention of NAS within the scope of practice of the Family Nurse 
Practitioner, utilizing concepts applied from the perspective of Sister Callista Roy’s Adaptation 
Model. No particular nursing theory was provided in the articles evaluated for this literature 
review.  
Definition of Terms 
Adaptation: A process of responding to environmental changes (Current Nursing, 2012). 
Neonatal Abstinence Syndrome:  NAS is a cluster of symptoms exhibited by the baby which 
indicates physiological response to the immediate withdrawal of maternal drug use 
(Ramakrishnan, 2014). 
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Opioid: A class of drug that binds to opioid receptors (mu, delta, kappa) to produce supraspinal 
analgesia by acutely inhibiting the release of noradrenaline at synaptic terminals (Hudak & Tan, 
2012). 
Roy’s Adaptation Model: A nursing theory that recognizes an individual as a combination of 
spiritual, biological, and psychological systems attempting to maintain equilibrium between the 
environment and these systems (Current Nursing, 2012). 
Theoretical Framework 
 The theoretical framework chosen for this review is based on Sister Callista Roy’s 
Adaptation Model. Major assumptions of this theory are based on the hypothesis that an 
individual is in constant interaction with a changing environment and attempts to cope with this 
using both innate and acquired mechanisms which are biological, psychological, and social in 
origin (Roy, 2011). Roy’s Adaptation Model focuses on the person as an open, adaptive system 
using coping skills to deal with stressors (Alligood, 2010).  Roy sees the environment as a factor 
that surrounds and affecst the development of the person. Health is manifested by the person’s 
ability to adapt, and an unhealthy state is a result of three types of stressors: focal, contextual, or 
residual. In the case of NAS, an infant is exposed to an environmental stressor, opiates, in-utero. 
Maternal opiate use subjects the fetus to exposure through equilibrium between the maternal and 
fetal circulation, and the fetus undergoes adaptation to the in-utero environment. The cessation of 
the maternal supply of the drug at birth can result in the onset of withdrawal symptoms in the 
neonate, resulting in focal stimuli stressors that can lead to an unhealthy state for the neonate.  
The presenting symptoms of withdrawal are a result of dysregulation of central, autonomic, and 
gastrointestinal functioning, and these symptoms can lead to a state of poor adaptation. The goal 
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of intervention is to promote adaptation and achieve a state of optimal health. Table A1 outlines 
the four concepts defined by Roy’s Adaptation Model (Current Nursing, 2012) 
Statement of Purpose 
 The purpose of this literature review is to present current knowledge of Neonatal 
Abstinence Syndrome to promote awareness among Family Nurse Practitioners.  This 
information will serve as a guide in intervention and prevention strategies, utilizing best 
evidence, toward reduction in the occurrence of NAS applying concepts from Roy’s Adaptation 
Model.   
Chapter 2: Literature Review 
Methods  
 Criteria for the literature review was limited to current articles that targeted all issues 
related to Neonatal Abstinence Syndrome and management thereof. The literature search was 
completed using the online CINAHL, Ovid, and MEDLINE information sources.  Current 
demographic information was obtained through a web-based search.   The phrases used in the 
literature search contained the following; “neonatal abstinence syndrome,” “primary care and 
neonatal abstinence syndrome,” “opioid abuse,”  “maternal drug use,” and “substance abuse 
during pregnancy,” with a date range of 2009 through 2014. The study selection process included 
only material that is scholarly and peer-reviewed.   
Results 
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The information obtained through the literature review was divided into the following 
categories: background, etiology, pathophysiology, clinical manifestations, tools of assessment, 
management, outcomes, and prevention strategies.  
Background  
 As early as 1969, pediatrician Loretta Finnegan began documenting withdrawal 
symptoms of newborns born to mothers that were drug dependent (Nelson, 2013). An emerging 
rise in the incidence of newborns with a passive addiction to heroin was observed in 1974, and 
Finnegan and MacNew identified a need for specific assessment and management of the 
condition (Maguire, Cline, Parnell, & Tai, 2013).  The expression of NAS symptoms depends on 
the substance or combination of substances, extent of exposure, and timing of maternal exposure 
prior to delivery, with 50 to 90 percent experiencing withdrawal after opiate exposure alone (Bio, 
Siu, & Poon, 2011).  The transient withdrawal associated with maternal drug use could have 
long-term neurodevelopmental effects on the neonate (Newman, 2014).   
Etiology 
NAS is a result of either iatrogenic or passive exposure to opioids. The focus of this 
review is passive exposure through maternal use of opioids or opioid derivatives, which results 
in the development of physical dependence on the substance by the infant. When the cord is 
clamped at birth, the combination of the sudden withdrawal from the drug, change in 
metabolism, and increased excretion result in elimination of the drug from the infant’s system. 
This process leads to the onset of symptom development in the neonate. The diagnosis of NAS is 
made based on the infant’s history and evidence of exposure obtained from infant and/or 
maternal drug screen and clinical signs of exposure (Lucas & Knobel, 2012).  
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 Opioids, the causative agent of NAS, include agonists and mixed agonists-antagonists.  
The agonists include heroin, morphine (including prodrug codeine), fentanyl, methadone, 
oxycodone, meperidine, hydromorphone, tramadol, and propoxyphene. Mixed agonists-
antagonists include buprenorphine, butorphanol, nalbuphine, and pentazocine (Jansson, Velez, & 
Harrow, 2009).  The agonist effects of opioids include supraspinal analgesia, sedation, euphoria, 
respiratory depression, and decreased gastrointestinal motility.  Opioids inhibit the release of 
noradrenaline at synaptic terminals (Ordean & Chisamore, 2014). Opiates are known to rapidly 
cross the placenta, creating equilibrium between the maternal and fetal circulation (Behnke & 
Smith, 2013).  
Pathophysiology 
 The pathophysiology of NAS involves mechanisms that facilitate transplacental passage: 
active transport, passive diffusion, and pinocytosis.  Factors that affect transport include the size 
of the drug molecule, its lipophilicity, the acid ionization constant of the compound, and pH of 
the blood.  Upon clamping of the cord at delivery, the transport of the drug is discontinued 
leading to the onset of a withdrawal syndrome in the neonate (MacMullen, Dulski, & Blobaum, 
2014). Opioid receptors are located in the central nervous system and the gastrointestinal tract.  
Therefore, the cessation of opioids leads to withdrawal causing central nervous system 
irritability, over-reactivity in the autonomic nervous system, and gastrointestinal dysfunction 
(Hudak & Tan, 2012). 
Clinical Manifestations  
 When assessing the clinical manifestations of NAS, it is important to consider that many 
infants are poly-drug exposed to licit and illicit substances, as well as alcohol and nicotine, and 
NAS                      9  
 
this contributes to the overall symptoms exhibited by a neonate (Jansson, Velez, & Harrow, 
2009).  This complicates medical management due to the exacerbation of signs and symptoms of 
NAS (Lucas & Knobel, 2012).  Full term infants exhibit more severe and earlier onset of 
symptoms when compared to preterm infants due to the developmental immaturity of central 
nervous system functioning (Newman, 2014).  Decreased severity of symptoms in the preterm 
infant may be related to differences in drug exposure totals and decreased fat deposits of the drug 
(Hudak & Tan, 2012). The presentation of clinical symptoms varies with the opioid used, the 
history and timing of maternal use, maternal poly-drug abuse, maternal and infant metabolism, 
transplacental passage of the drug, placental metabolism, and infant excretion. The expression of 
NAS is also affected by environmental factors and infant hunger (Lucas & Knobel, 2012).  
Symptoms are unpredictable and can be related to many factors at the time of delivery, or 
for weeks after delivery.  These symptoms can be subacute for a period as long as six months 
with potential neurodevelopmental problems evident until approximately 12 months of age 
(Lucas & Knobel, 2012). NAS symptoms are manifested in a multi-system presentation related 
to the location of opioid receptors. Central nervous system (CNS) symptoms include: irritability, 
increased wakefulness, high-pitched cry, tremors, increased muscle tone, hyperactive deep 
tendon reflexes, frequent yawning, frequent sneezing, and seizures. Gastrointestinal symptoms 
include: vomiting, diarrhea, dehydration, poor weight gain, and poor feeding.  Autonomic 
symptoms include: diaphoresis, nasal stuffiness, mottling, fever, temperature regulation issues, 
tachypnea, hypertension, and piloerection (Hudak & Tan, 2012).  
Underlying medical conditions can present with symptoms similar to the clinical 
manifestations of NAS.  A thorough assessment is required to exclude possible differential 
diagnoses.  These conditions include: infections, hyperthyroidism, hypoglycemia, hypocalcemia, 
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hypomagnesaemia, trauma, anoxic brain injury, or intracranial hemorrhage (Bio, Siu, & Poon, 
2011).   Other conditions requiring consideration as potential differential diagnoses are hypoxic 
ischemic encephalopathy and polycythemia hyperviscosity syndrome (Ordean & Chisamore, 
2014).  
Tools of Assessment 
 In 1975, pediatrician Loretta Finnegan developed a scoring system, known today as the 
Finnegan Score, to assess clinical symptoms exhibited by newborns (Ordean & Chisamore, 
2014).  The American Academy of Pediatrics recommends utilizing standardized assessment 
tools for scoring clinical symptoms such as the Finnegan method, the Ostrea system, or the 
Lipsitz tool (Lucas & Knobel, 2012). 
The Finnegan Neonatal Abstinence Scoring Tool, FNAST, is an instrument used to 
determine the severity of symptoms of withdrawal in infants subjected to opioids in-utero. The 
FNAST is the most frequently used assessment tool used in clinical practice management of 
NAS (D'Apolito, 2014). The tool can be seen in Table A2. 
Management 
 Overall management of NAS begins with appropriate maternal screening during 
pregnancy.  Gathering information regarding potential drug exposure when obtaining prenatal 
patient histories is essential in identification of NAS risk. Self-reporting is a practical method of 
obtaining information, yet a biological specimen can more accurately determine substance use 
during pregnancy (Behnke & Smith, 2013).   The American College of Obstetricians and 
Gynecologists (ACOG) recommends the use of a screening tool to assist in identification of drug 
use risk. Signs of a substance use disorder in a pregnant woman include seeking prenatal care 
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late in pregnancy, poor adherence to appointments, poor weight gain, symptoms of sedation, 
intoxication, withdrawal, or erratic behavior (Nelson, 2013). The 4P’s Plus and the Substance 
Use Risk Profile, Pregnancy Scale were designed specifically for screening pregnant women. 
Regulatory guidelines regarding maternal drug screening using biological methods vary by state 
and practice policies (Goodman & Wolff, 2013). The 4P’s Plus is a four-question tool designed 
to identify patients at risk for alcohol or illicit drug use (Chasnoff, et al., 2005).  The 
questionnaire can be seen in Table A3.  
Untreated withdrawal of the opioid exposed fetus is linked to preterm labor and fetal 
death. The risk of fetal loss has been successfully abated with the use of methadone and 
buprenorphine replacement therapy during pregnancy.  Maternal treatment for opioid abuse 
during pregnancy has demonstrated improved prenatal care and participation adherence in 
substance abuse counseling (Pritham, 2013).  In 2005, only six percent of pregnant women that 
were categorized as needing substance abuse treatment received it as recommended 
(Ramakrishnan, 2014). 
Management of infants at risk for NAS begins at birth with observation, monitoring of 
vital signs, and utilization of scoring tools to assess for symptom development (Jansson, Velez, 
& Harrow, 2009). The timing and expression of NAS symptoms are variable and depend on the 
substance the neonate was exposed to (Bio, Siu, & Poon, 2011). Nonpharmacologic treatment of 
NAS includes reduction of environmental stimuli, positioning, swaddling, and breastfeeding. 
Breastfeeding, by women that are without contraindications, is supported by The American 
College of Obstetricians and Gynecologists, the American Academy of Pediatrics, and the 
Academy of Breastfeeding Medicine. Breastfeeding offers improved outcomes for the NAS 
affected neonate related to decreased severity and duration of symptoms, as well as enhanced 
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maternal attachment and bonding (Pritham, 2013).  Rooming in with mothers has improved the 
outcome for NAS infants and demonstrated a diminished need for pharmacologic therapy 
(Ramakrishnan, 2014). 
The first line pharmacologic treatment of the infant with NAS are opiates, Neonatal 
Morphine Solution (NMS), or combinations of opiates and phenobarbital or clonidine, to 
diminish symptom duration.  Dosages are based on symptoms and infant weight. The overall 
length of hospital stay is dependent on the successful weaning of the infant from the opiates 
(Pritham, 2013).  Medication regimens that are specific to poly-drug exposure provide beneficial 
adjunct therapy for infants with atypical NAS presentation (Ramakrishnan, 2014).   
The average hospitalization for an infant with NAS is 30 days, followed by further 
outpatient monitoring by a primary care provider to assess infant growth and neurodevelopment 
(Backes, et al., 2011). Long-term management of infants with NAS should include sensory 
processing with occupational therapy, speech therapy, and physical therapy for improved motor 
function.  Behavior modification management may be necessary and provision of a consistent 
environment with support of family, day care, or school programs is suggested. Medications are 
recommended on an individualized basis as needed for management of issues related to risk of 
attention deficits/hyperactivity, impulsivity control, and aggressive behaviors (Behnke & Smith, 
2013).  
Outcomes 
 The major short-term effect of opiate exposure in-utero is neonatal abstinence syndrome.  
The long-term outcome of opiate exposure has led to documented delayed fetal growth as well as 
long-term effects on neurocognitive function, sensory integration, mood and temperament, and 
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dysregulation from birth through three years of age. There is not a consensus on the effects, long-
term, on cognition.  There have been limited studies of the long-term effects of intrauterine 
opiate exposure on language and achievement (Behnke & Smith, 2013).  There is an increased 
risk of both motor and cognitive developmental delays after methadone exposure in-utero. 
Logan, Brown, & Hayes (2013) studied drug exposed infants at nine months of age, and found 
that 37.5% of the sample had documented motor delays. The study also confirms that other 
factors, including poly-drug exposure, environmental, and medical issues, may play a role in the 
negative outcomes in this population (Logan, Brown, & Hayes, 2013). 
Prevention Strategies  
 The American Nurses Association has issued a position statement encouraging the 
promotion of addiction treatment and social support over criminalization of women with 
substance abuse problems. Their position also focuses on a primary solution to perinatal 
substance abuse by supporting rehabilitation and therapy for treatment (American Nurses 
Association, 2011).  Strategies of NAS prevention include promoting awareness of the effects of 
drug use during pregnancy, screening, intervention and referrals to treatment, and the promotion 
of regular prenatal care (Ramakrishnan, 2014). An understanding of the pathophysiology of NAS 
can lead to optimal outcomes for infants (Jansson, Velez, & Harrow, 2009). Other strategies of 
prevention include the promotion and maintenance of optimal health by primary care providers 
through the process of obtaining thorough and complete patient histories and screening those at 
risk for substance abuse (Behnke & Smith, 2013). Nelson states “Neonatal Abstinence Syndrome 
is a growing nursing, medical, social and psychological issue. Though this problem is 100% 
preventable, it is an issue that needs to be addressed from all disciplines” (Nelson, 2013).  The 
Maternal Opioid Treatment: Human Experimental Research study, MOTHER, discussed the 
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significant consequences of opiate dependence on both maternal and infant health, determining 
that appropriate treatment would improve patient outcomes (Jones, et al., 2010).  Dr. Michael 
Warren, Division of Family Health and Wellness for the State of Tennessee Department of 
Health, adapted a CDC framework into a chart with recommended Levels of Prevention of NAS. 
The chart is presented in table A4.  
Chapter 3: Discussion 
Synthesis of Research  
 This literature review has provided an overview of the neonatal drug withdrawal 
condition known as Neonatal Abstinence Syndrome.  The literature identifies the increasing 
prevalence of NAS and the correlation of the condition with maternal opioid use. The clinical 
manifestations of NAS are identified to assist the primary care provider in early diagnosis to 
promote improved outcomes for the infant. Tools used to assess the risk of maternal substance 
abuse and scoring tools to monitor the severity of the symptoms experienced by the infant were 
reviewed and serve as evidenced-based guidelines in management of the condition. Management 
techniques presented in the literature included pharmacologic and non-pharmacologic methods.  
The findings of this review support the importance of prevention, early recognition, and follow 
up for improved long-term outcomes.   
Limitations  
 The major limitation of this literature review is the lack of data regarding the long-term 
effects of NAS on children.  Multiple studies were found regarding the short-term effects of 
NAS, but there were limited studies found that provide information regarding the overall 
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longitudinal effects and management of the condition. Further studies that explore the long-term 
issues related to NAS would be necessary to improve outcomes.  
Chapter 4: Conclusion 
 Neonatal Abstinence Syndrome is a growing concern due to the increasing number of 
infants diagnosed with the condition. Caring for infants with NAS, their families, or caregivers, 
can present a challenge for primary care providers. Family Nurse Practitioners have the 
opportunity to assess the pregnant woman for risks of opiate use and to observe and intervene 
when signs and symptoms are observed in their fragile infants. Evidence supports the 
continuation of management of NAS after hospitalization and the need for comprehensive care 
by primary care providers through a multidisciplinary approach.  Providing primary care to 
women of childbearing age and integrating screening techniques with appropriate early 
intervention can decrease the risk of NAS. Establishing consistent quality care with a 
nonjudgmental attitude, compassion, and an evidenced-based approach can lead to improved 
outcomes for NAS-affected infants and their families.  
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Appendix A 
Table A1 Definition of Domain Concepts by Sister Callista Roy 
Person Nursing Health Environment 
The Person is a 
biopsychosocial being in 
constant interaction with a 
changing environment. 
The person is an open, 
adaptive system who uses 
coping skills to deal with 
stressors. The NAS infant 
faces challenges in 
adaptation when 
transitioning after drug 
exposure in the 
intrauterine environment. 
The goal of nursing is to 
promote adaptation in the 
four adaptive modes, thus 
contributing to health, 
quality of life, by assessing 
behaviors and factors that 
influence adaptive abilities 
and by intervening to 
enhance environmental 
interactions. Intervention 
assists the NAS infant in 
coping to achieve optimal 
health through 
pharmacologic and non-
pharmacologic techniques. 
An inevitable dimension of 
a person's life, represented 
by a health-illness 
continuum. A state and a 
process of being and 
becoming integrated and 
whole. Attaining a state of 
health for the NAS infant 
is represented by being 
symptom-free and 
appropriately reaching 
growth and 
neurodevelopmental 
milestones. 
All conditions, 
circumstances, and 
influences surrounding and 
affecting the development 
and behavior of persons 
and groups with particular 
consideration of mutuality 
of person and earth 
resources, including focal, 
contextual and residual 
stimuli. Optimal Health for 
the NAS infant is obtained 
through a drug-free 
environment. 
(Alligood, 2010) 
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Table A2 Finnegan Neonatal Abstinence Scoring Tool 
 
 
 
(D'Apolito, 2014) 
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Table A3 4 P’s Plus  
 Parents  Did either of your parents have a problem with alcohol or drugs? 
 
 Partner   Does your partner have a problem with alcohol or drugs? 
 
 Past   Have you ever drank beer, wine, or liquor? 
 
 Pregnancy  In the month before you knew you were pregnant, how many  
                                    cigarettes did you smoke?   
  
   In the month before you knew you were pregnant, how many   
   beers/how much wine/how much liquor did you drink? 
(Chasnoff, et al., 2005)  
 
   
                      
Table A4
 
(Warren, 2013) 
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Appendix B Matrices 
Title  
 
Purpose  
Objective, 
Hypotheses, or 
Study Questions 
Population  
Sample 
Inclusion / 
Exclusion Criteria 
Interventions/ 
Variables  
Measurements 
 
Study 
Design/ 
Level of 
Evidence 
 Findings/ 
Limitations 
 
Article 1 
 
Backes, C. H., Backes, C. 
R., Gardener, D., Nankervis, 
C. A., Giannone, P. J., & 
Cordero, L. (2011). 
Neonatal abstinence 
syndrome: transitioning 
methadone-treated infants 
from an inpatient to an 
outpatient setting. Journal of 
Perinatology, 425-430. 
 
To compare safety and 
efficacy of a traditional 
inpatient only approach 
with a combined 
inpatient and outpatient 
methadone treatment 
program for 
pharmacologic treatment 
of NAS. 
Population 
characterization: 
Infants born to 
mothers maintained 
on methadone.  
 
Sample Size: 
N=121 
Inpatient: 75 infants 
Combined: 46 infants 
 
Inclusion: Infants 
with history of 
maternal 
methadone use.  
 
Exclusion: Infants 
with history of 
maternal illicit drug 
use (cocaine, heroin, 
etc.) 
 
  
 
 
 
IV: Demographics, 
Obstetrical Risk Factors, 
Birth Weight,  
Gestational Age,  
Incidence of prematurity 
 
DV: Duration of  
Hospital Stay, 
Length of Treatment, 
Outpatient Follow up 
 
Instrument: 
Finnegan Scoring System 
Retrospective  
Review 
 
Level of 
Evidence: IV 
Findings: 
The average hospitalization 
for an infant with NAS is 30 
days, followed by further 
outpatient monitoring by a 
primary care provider to 
assess infant growth and 
neurodevelopment. Hospital 
stay was shorter in the 
combined group (13 vs 25 
days; P<0.001) 
 
Treatment was longer for 
infants in the combined group 
(37 vs 21 days; P<0.01) 
 
Combined treatment decreases 
hospital stay and substantially 
reduces cost in treatment of 
NAS.  
 
Limitations: 
 Retrospective Design 
 
 Small study 
Population 
 
Title 
 
Purpose  
Objective, 
 Hypotheses,  
or Study Questions 
Population 
Sample 
Inclusion / 
Exclusion Criteria 
Interventions/ 
Variables 
Measurements 
 
Study 
Design/ 
Level of 
Evidence 
 Findings/ 
Limitations 
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Article 2 
 
Behnke, M., & 
Smith, V. C. 
(2013). Prenatal 
Substance Abuse: 
Short and Long-
term Effects on the 
Exposed Fetus. 
Pediatrics, e1009-
e1024.   
 
To review data regarding the 
prevalence of prenatal 
substance abuse and the 
short and long-term effects 
on exposed infants. The aim 
of the study was to facilitate 
pediatricians in promotion 
and maintenance of infant 
and child health.  
Population 
Characterization: 
Infants born to 
substance abusing 
women between 15 and 
45 years old.  
 
 
Inclusion criteria: 
Exposure to: nicotine, 
alcohol, marijuana, 
opiates, cocaine, and 
methamphetamine.  
 
 
 
 
 
 
IV: Maternal history, 
Drugs or combinations of 
drugs used,  
Testing of biological 
specimens,  
Biological specimen type; 
hair, urine, or meconium,  
Screening techniques 
 
DV: Fetal growth, 
congenital anomalies, 
withdrawal symptoms, 
neurobehavioral, cognitive 
functioning, language, 
achievement, Predisposed 
to drug use. 
 
Instruments: 
Maternal survey forms for 
self-reporting 
Biological specimen 
screening (immunoassay) 
 
Systematic 
Review 
 
Level of 
Evidence: 
V 
Findings: 
Opiates are known to rapidly 
cross the placenta, creating 
equilibrium between the maternal 
and fetal circulation. The findings 
were broken down into short-term 
and long-term effects by specific 
drug exposure. The most 
significant effect of prenatal 
opiate exposure is neonatal 
abstinence syndrome.  
 
Limitations: 
Methodological differences 
between studies and limited data 
in the extant literature make 
generalizations of the results 
difficult.  
 
 
 
 
 
Title 
 
Purpose  
Objective, 
Hypotheses or 
Study 
Questions 
Population  
Sample 
Inclusion / 
Exclusion Criteria 
Interventions/ 
Variables 
Measurements 
 
Study 
Design/ 
Level of 
Evidence 
 Findings/ 
Limitations 
Article 3 
 
Bio, L. L., Siu, A., & 
Poon, C. Y. (2011). 
Update on the 
Pharmacologic 
Management of 
Neonatal Abstinence 
Syndrome. Journal of 
To review the 
management of 
infants diagnosed 
with NAS due to 
opioid or 
polysubstance 
exposure. 
Population 
Characterization: 
Neonates exposed to 
opioid or 
polysubstance 
exposure. 
 
 
 
IV: Pharmacokinetics of the 
agent, Gestational Age, 
Total amount of exposure 
(time), 
Fetal Growth, 
Prematurity, Birth Weight 
 
DV:  
Manifestations of NAS 
Design: 
Systematic 
Review of 
Literature  
 
Level of 
Evidence: 
V 
Findings: 
A thorough assessment is required to 
exclude possible differential diagnoses.  
These conditions include infections, 
hyperthyroidism, hypoglycemia, 
hypocalcemia, hypomagnesaemia, 
trauma, anoxic brain injury, or 
intracranial hemorrhage. Oral morphine 
solution was found to be the preferred 
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Perinatology, 695-701   Neurological  
 Gastrointestinal 
 Autonomic 
 
Instruments: 
Finnegan Scoring System 
 
 
 
drug to treat NAS and is recommended 
by AAP. Non-opioid therapies can be 
beneficial in treatment of NAS.  
 
Title 
 
Purpose  
Objective, 
Hypotheses or 
Study Questions 
Population  
Sample 
Inclusion / 
Exclusion Criteria 
Interventions/ 
Variables 
Measurements 
 
Design 
Level of 
Evidence 
 Findings/ 
Limitations 
Article 4 
 
Chasnoff, I. J., McGourty, R. F., 
Bailey, G. W., Hutchins, E., 
Lightfoot, S. O., Pawson, L., & 
Campbell, J. (2005). The 4P’s 
Plus© screen for substance use in 
pregnancy:  clinical application and 
outcomes. Journal of Perinatology, 
25(6), 368-374.  
 
To determine the 
prevalence of 
substance use among 
pregnant women in 
five diverse 
communities utilizing 
the 4P’s Plus© screen 
for alcohol, tobacco, 
and other drug use.  
Population 
Characterization: 
Pregnant women 
enrolled in prenatal care 
clinics with positive 
screen. 
 
Sample size: 
N=1548 
 
Inclusion Criteria: 
Any woman who had 
evidence of any alcohol 
or illicit substance abuse 
during pregnancy. 
 
Exclusion Criteria:  
Non-substance using 
pregnant woman. 
 
 
 
 
 
IV: Alcohol use, 
cigarette use, 
alcohol and 
cigarette use 
reported on 
screening tool. 
 
DV: Screening 
results 
determining 
substance abuse. 
 
Instrument: 4P’s 
Plus© Screening 
Tool 
Study Design: 
Non-randomized, 
well designed 
study 
 
Level of 
Evidence: III 
Findings:  
The 4P’s Plus is a four-
question tool designed to 
identify patients at risk for 
alcohol or illicit drug use. 
Among the population 
with a positive screen, 717 
(15%) of the population 
continued using the 
substance after learning of 
the pregnancy. Overall, 
21% of the women used 
alcohol prior to the 
recognition of pregnancy 
and 11% continued to use 
after knowledge of the 
pregnancy. The rates of 
marijuana and other illicit 
drug use among the 
women were 7 and 2%, 
respectively, prior to 
pregnancy, and dropped to 
3 to 1% after learning of 
the pregnancy. The 
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screening tool provides an 
opportunity for early 
intervention.  
 
Limitations: Screening 
tools are often focused on 
targeted populations rather 
than the general 
population. 
 
Title 
 
Purpose  
Objective, 
Hypotheses or 
Study Questions 
Population 
Sample 
Inclusion / 
Exclusion Criteria 
Interventions/ 
Variables 
Measurements 
 
Design/ 
Level of 
Evidence 
 Findings/ 
Limitations 
Article 5 
 
D’Apolito, K. (2014). Assessing 
Neonates for Neonatal Abstinence. 
Journal of Perinatology and Neonatal 
Nursing, 220-231.  
To review the 
elements of the 
Finnegan Scoring Tool 
and describe a way to 
improve the accuracy 
and consistency of 
scoring infants for 
signs of withdrawal 
using an interobserver 
reliability approach.   
Population 
Characterization: 
Nurses, 
(raters/observers) 
taking care of infants 
exposed to opioids in-
utero that are 
exhibiting withdrawal 
symptoms.  
 
Sample Size: 
N=1647 
 
Inclusion criteria:  
Participant training 
utilizing videos and 
testing with 90% 
reliability. 
 
Exclusion criteria: 
Participant fails to 
achieve 90% on 
testing after training.  
 
IV: Assessment of 
signs of 
withdrawal:  
Central Nervous 
System 
Crying, Sleep 
patterns, Moro 
Reflex, Tremors, 
Increased muscle 
tone, Excoriation, 
Myoclonic jerks, 
Generalized 
Convulsions 
Metabolic, 
vasomotor, and 
respiratory  
Sweating, Fever, 
Frequent yawning, 
Mottling, Nasal 
Stuffiness, 
Respiratory Rate 
Gastrointestinal 
Excessive sucking, 
Poor feeding, 
Study Design: 
Descriptive 
design examining 
relationships. 
 
Level of 
Evidence: 
VI 
 
Findings: 
The FNAST is the most 
frequently used 
assessment tool used in 
clinical practice 
management of NAS. 
Results revealed that our 
of 1647 interobserver 
reliability checks, 45% 
were not performed at 
the same time.  Findings 
determine that it is 
important to perform the 
interobserver reliability 
assessment at the same 
time between the two 
observers. 
 
Limitations: 
Timing of the 
interobserver reliability 
check is critical in 
obtaining accurate 
results.  
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Regurgitation, 
Projectile 
Vomiting, Loose 
stools/Watery 
Stools 
DV: Equal scoring 
by each observer 
Instruments: 
Finnegan Scoring 
Tool used by 2 
independent raters. 
 
 
 
 
 
Title 
 
Purpose  
Objective, 
Hypotheses or 
Study Questions 
Population 
Sample 
Inclusion / 
Exclusion Criteria 
Interventions/ 
Variables 
Measurements 
 
Design/ 
Level of 
Evidence 
 Findings/ 
Limitations 
Article 6 
 
Goodman, D. J., & 
Wolff, K. B. (2013). 
Screening for 
Substance Abuse in 
Women’s Health: A 
Public Health 
Imperative. Journal 
of Midwifery & 
Women’s Health, 
278-287.   
 
To provide a review 
of screening tools 
available to 
providers in both 
prenatal and 
primary women’s 
health care settings.  
Population 
Characterization: 
Women’s Health Care 
Providers providing 
primary care and care 
during pregnancy. 
 
 
 
 
 
 
IV: Prevalence of drug and 
alcohol use during pregnancy, 
variations in practice, 
screening integration, follow 
up, screening tools, 
intervention techniques, 
referral for treatment, and 
comorbid conditions. 
 
DV: 
Improved perinatal outcomes 
 
Instruments: Multiple 
screening tools were 
reviewed: 
ASSIST 
AUDIT-C 
CRAFFT 
4P’s Plus© 
Substance Use Risk Profile 
Pregnancy Scale 
T-ACE 
Study 
Design: 
Retrospective 
 
 
Level of 
Evidence: 
IV 
 
Findings: 
Screening for substance use and 
dependence is an essential component 
of women’s health care. Addressing 
the problem leads reduces lifelong 
morbidity and mortality for women, 
and prevents or reduces exposure 
during pregnancy. Perinatal outcomes 
are improved with substance abuse 
screening and appropriate treatment. 
The 4P’s Plus© screening tool is 
developed specifically for pregnant 
women. 
Approximately 11% of pregnant 
women reported using alcohol, 
tobacco, or illicit substances during 
pregnancy in 2009 National Survey on 
Drug Use and Health.  
 
Limitations: 
Screening can have ethical 
implications.  
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TICS 
TWEAK 
 
 
 
 
 
Title 
 
Purpose  
Objective, 
Hypotheses or 
Study Questions 
Population 
Sample 
Inclusion / 
Exclusion Criteria 
Interventions/ 
Variables 
Measurements 
 
Design/ 
Level of 
Evidence 
 Findings/ 
Limitations 
Article 7 
 
Hudak, M. L., & Tan, R. C. 
(2012). Neonatal Drug 
Withdrawal. Pediatrics, 
540-560. 
To provide 
information about the 
clinical presentation 
of infants exposed to 
intrauterine drugs and 
the therapeutic, 
evidence-based 
options for treatment 
and management of 
withdrawal. 
Population 
Characterization: 
Infants exposed to 
intrauterine illicit 
drugs. 
 
Inclusion criteria:  
Infants exposed to 
Drugs of Abuse: 
Opioids, CNS 
Stimulants, CNS 
Depressants, 
Hallucinogens. 
 
Exclusion criteria: 
Non-exposed infants 
or iatrogenic exposed 
infants. 
 
IV:  
Clinical Symptoms:  
Central Nervous System 
Crying, Sleep patterns, 
Moro Reflex, Tremors, 
Increased muscle tone, 
Excoriation, Myoclonic 
jerks, Generalized 
Convulsions 
Metabolic, vasomotor, and 
respiratory  
Sweating, Fever, Frequent 
yawning, Mottling, Nasal 
Stuffiness, Respiratory Rate 
Gastrointestinal 
Excessive sucking, Poor 
feeding, Regurgitation, 
Projectile Vomiting, Loose 
stools/Watery Stools 
 
Medication management 
using medications per 
protocols to affect response. 
 
DV: 
Decreased severity of 
symptoms with medication 
management. 
 
Instruments: 
Study 
Design: 
Quasi-
experimental 
Design  
 
Level of 
Evidence: 
III 
 
Findings: 
In 1975, a syndrome of 
opiate withdrawal in 
newborns was first 
described by Finnegan. 
Protocols should be 
standardized for each 
nursery caring for infants 
with NAS. Screening for 
maternal substance abuse is 
essential. Maternal reporting 
of illicit drug use is most 
likely lower when self-
reporting when compared to 
results of biologic 
screening, leading to 
underestimated actual rates 
of intrauterine drug 
exposure. Rule out 
differential diagnosis for 
infants with symptoms of 
NAS. Use scoring tool to 
measure symptoms of drug 
withdrawal. Breastfeeding 
should be encouraged. 
Tables with recommended 
dosing of oral morphine, 
methadone, and clonidine 
are provided. Outpatient 
follow up of infants with 
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Weaning protocols: Four 
tables provided 
Finnegan Scoring 
 
NAS is critical.  
 
Limitations: 
Further randomized 
controlled studies to 
measure pharmacologic 
therapy and weaning 
strategies should are 
necessary to assess short-
term outcomes and provide 
for long-term follow up.  
 
 
 
 
 
Title 
 
Purpose  
Objective, 
Hypotheses or 
Study Questions 
Population 
Sample 
Inclusion / 
Exclusion Criteria 
Interventions/ 
Variables 
Measurements 
 
Design/ 
Level of 
Evidence 
 Findings/ 
Limitations 
Article 8 
 
Jansson, L. M., Velez, M., 
& Harrow, C. (2009). The 
Opioid Exposed Newborn:  
Assessment and 
Pharmacologic 
Management. Journal of 
Opioid Management, 47-55.  
To provide the health 
care provider with a 
review of current 
evidence and 
practical guidelines 
for optimal 
evaluation and 
pharmacologic 
management of the 
opiate exposed 
newborn.  
Population 
Characterization: 
Opiate exposed 
newborns with 
withdrawal symptoms. 
 
Inclusion criteria:  
Maternal history of 
opiate use during 
pregnancy. 
 
Exclusion criteria: 
Non-opiate exposed 
infant 
 
 
 
 
IV: Symptoms exhibited: 
Central Nervous System 
Crying, Sleep patterns, 
Moro Reflex, Tremors, 
Increased muscle tone, 
Excoriation, Myoclonic 
jerks, Generalized 
Convulsions 
Metabolic, vasomotor, and 
respiratory  
Sweating, Fever, Frequent 
yawning, Mottling, Nasal 
Stuffiness, Respiratory Rate 
Gastrointestinal 
Excessive sucking, Poor 
feeding, Regurgitation, 
Projectile Vomiting, Loose 
stools/Watery Stools 
Study 
Design: 
Systematic 
Review 
 
Level of 
Evidence: 
V 
 
Findings: 
Standardized assessment 
and treatment protocols for 
early identification and 
appropriate treatment for 
opioid exposed infants are 
needed for optimal 
management. Symptom 
based treatment would be 
optimal when compared to 
weight based treatment to 
reduce replacement 
medication therapy. 
 
Limitations: 
Small numbers and use of 
convenience sampling could 
present limitations.  
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DV: 
Symptom relief or 
improvement of symptoms 
 
Instruments: 
Finnegan Scoring 
Lipsitz Neonatal Drug-
Withdrawal Scoring System 
Neonatal Withdrawal 
Inventory 
Neonatal Narcotic 
Withdrawal Index 
 
 
 
 
 
Title 
 
Purpose  
Objective, 
Hypotheses or 
Study Questions 
Population 
Sample 
Inclusion / 
Exclusion Criteria 
Interventions/ 
Variables 
Measurements 
 
Design/ 
Level of 
Evidence 
 Findings/ 
Limitations 
Article 9 
 
Jensen, C. (2014). 
Improving outcomes for 
infants with NAS. The 
Clinical Advisor, 85-91.  
 
To present strategies 
that will improve 
outcomes for infants 
with NAS. 
Population 
Characterization: 
Newborns exposed to 
illegal or prescription 
drugs during 
pregnancy. 
 
Inclusion criteria:  
Infants diagnosed with 
NAS 
 
Exclusion criteria: 
Non-exposed infants 
 
 
 
 
 
IV:  
Symptoms of NAS: 
Central Nervous System 
Crying, Sleep patterns, 
Moro Reflex, Tremors, 
Increased muscle tone, 
Excoriation, Myoclonic 
jerks, Generalized 
Convulsions 
Metabolic, vasomotor, and 
respiratory  
Sweating, Fever, Frequent 
yawning, Mottling, Nasal 
Stuffiness, Respiratory Rate 
Gastrointestinal 
Excessive sucking, Poor 
feeding, Regurgitation, 
Projectile Vomiting, Loose 
stools/Watery Stools 
 
Study Design: 
Systematic 
Review 
 
Level of 
Evidence: 
V 
 
Findings: 
Prevalence of NAS is 
increasing due to increased 
use of illicit drugs by 
pregnant women. NAS 
symptoms can be managed 
with pharmacologic and 
non-pharmacologic 
measures. The quality of 
care the mother receives 
during pregnancy can 
greatly affect the outcome 
of the infant exposed to 
drugs in-utero. 
 
Limitations: 
Confounding variables 
may affect outcomes such 
as environmental factors, 
dysfunctional caregivers, 
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DV: 
Improvement or reduction 
of symptoms of NAS 
 
Instruments: 
Finnegan Scoring 
 
fetal growth problems, and 
polydrug exposure.  
 
 
 
 
 
Title 
 
Purpose  
Objective, 
Hypotheses or 
Study 
Questions 
Population 
Sample 
Inclusion / Exclusion Criteria 
Interventions/ 
Variables 
Measurements 
 
Design/ 
Level of 
Evidence 
 Findings/ 
Limitations 
Article 10 
 
Jones, H. E., Kaltenbak, K., 
Heil, S. H., Stine, S. M., 
Coyle, M. G., Arria, A. M., 
O’Grady, K. E., Selby, M. 
B., Martin, P. R., & Fischer, 
G. (2010). Neonatal 
Abstinence Syndrome after 
Methadone or 
Buprenorphine Exposure. 
The New England Journal 
of Medicine, 2320-2331.  
 
To conduct a 
randomized 
controlled trial 
comparing 
buprenorphine 
with methadone 
for treatment of 
opioid-dependent 
pregnant 
patients.  
Population Characterization: 
Opioid-dependent pregnant women 
between the ages of 18-41 years 
old with a singleton pregnancy 
between 6 and 36 weeks gestation 
at eight international sites.  
 
Sample: 
N=175 
 
Inclusion criteria:  
Women were eligible if they had 
no medical or other conditions 
contraindicating participation, no 
pending legal action, no disorders 
related to the use of 
benzodiazepines or alcohol, and 
did not plan to give birth outside 
the hospital at the study site.  
 
Exclusion criteria: 
No consent. 
Failed to meet inclusion criteria. 
Gestational age outside range. 
Benzodiazepine use. 
IV:  
Randomized 
dosing of 
Buprenorphine or 
Methadone 
 
DV: 
Neonates requiring 
treatment for NAS, 
Peak NAS Score, 
Total amount of 
morphine to treat 
NAS, 
Length of hospital 
stay, 
Neonatal head 
circumference 
 
Instruments: 
 Screening 
tests to 
meet 
inclusion 
criteria. 
 Finnegan 
Study 
Design: 
Descriptive/ 
RCT 
 
 
Level of 
Evidence: 
I 
 
Findings: 
Buprenorphine is an 
alternative to methadone for 
treatment of opioid 
dependency during 
pregnancy and should be 
considered as a first-line 
treatment in pregnancy. 
Public health and medical 
costs related to the care of 
infants diagnosed with NAS 
in 2009 was estimated 
between $70.6 million and 
$112.6 million in the United 
States. Detailed primary and 
secondary outcomes were 
broken down into tables. 
 
Limitations: 
Subpopulations of pregnant 
patients may likely have a 
variable response to one 
medication over another 
which could contribute to 
nonadherence. 
NAS                      32                                         
 
Medical complications 
Alcohol use. 
Legal issues. 
Psychological/psychiatric reason. 
Multiple-fetus pregnancy 
Outside age range. 
Detoxification. 
Did not speak English/German. 
Not opioid dependent. 
 
scoring 
 
 
 
 
 
 
 
Title 
 
Purpose  
Objective, 
Hypotheses 
or Study 
Questions 
Population 
Sample 
Inclusion / Exclusion 
Criteria 
Interventions/ 
Variables 
Measurements 
 
Design/ 
Level of 
Evidence 
 Findings/ 
Limitations 
Article 11 
 
Logan, B. A., Brown, M. S., 
& Hayes, M. J. (2013). 
Neonatal Abstinence 
Syndrome: Treatment and 
Pediatric Outcomes. Clinical 
Obstetrics and Gynecology, 
186-192. 
To examine the 
treatment and 
outcomes of 
prenatal opiate 
exposure on the 
neonate. 
Population Characterization: 
Infants exposed to maternal 
opiate use during pregnancy. 
 
Inclusion criteria:  
Maternal opiate dependence with 
prenatal fetal exposure. 
 
 
 
 
 
 
 
IV: Maternal 
Methadone dose-Low 
vs high 
Gestational exposure 
to benzodiazepines  
Breastfeeding 
 
DV:  
Length of stay, 
NAS severity 
Longer gestation 
 
Instruments: 
 Finnegan 
Scoring 
 NICU 
Network 
Neurobehavio
ral Scale 
 Bayley Scales 
of Infant 
Study Design: 
Descriptive-
Longitudinal/ 
Cohort study 
 
 
Level of 
Evidence: 
IV 
 
Findings: 
Maternal opiate 
dependence and fetal 
exposure presents 
complications; most 
notably NAS. Methadone 
is associated with 
improved stability of 
maternal and infant health 
when compared to illicit 
opiate use. Titration of 
methadone, prenatal care, 
and breastfeeding are 
recommended. Early 
intervention to manage 
treatment of NAS are 
recommended. 
 
Limitations: 
Further longitudinal studies 
of development are critical. 
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Development 
II 
 
 
 
Title 
 
Purpose  
Objective, 
Hypotheses or 
Study Questions 
Population 
Sample 
Inclusion / 
Exclusion Criteria 
Interventions/ 
Variables 
Measurements 
 
Design/ 
Level of Evidence 
 Findings/ 
Limitations 
Article 12 
 
Lucas, K., & Knobel, R. 
(2012). Implementing 
Practice Guidelines and 
Education to Improve Care 
of Infants with Neonatal 
Abstinence Syndrome. 
Advances in Neonatal Care, 
40-45.    
 
To evaluate change 
in nursing 
knowledge about 
NAS and the use of 
Finnegan Scoring 
after 
implementation of 
clinical guidelines 
and an educational 
program. 
Population 
Characterization: 
Nurses employed in 
NICU at single 
facility 
 
Sample Size- 
N=68 
 
Inclusion criteria:  
Nurses employed in 
NICU at site. 
 
 
 
 
 
Methods: 
Nurses were tested before 
and after participation in 
the educational 
presentation about NAS.  
Instruments: 
Finnegan Scoring System 
Study Design: 
Descriptive, non-
experimental 
 
Level of Evidence: 
V 
 
 
 
Findings: 
The diagnosis of NAS 
is made based on the 
infants history of 
exposure, evidence of 
exposure obtained from 
infant and/or maternal 
drug screen, and 
clinical signs of 
exposure. Symptoms of 
NAS can be subacute 
for a period delayed as 
long as six months with 
potential 
neurodevelopmental 
problems evident until 
approximately 12 
months of age. 
Evidence-based 
guidelines and 
education provide 
caregivers with tools to 
provide quality and 
accurate care to infants 
diagnosed with NAS. 
 
Limitations: 
Post-testing was done 
immediately after the 
educational 
presentation and may 
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not represent 
knowledge retained 
over any length of time. 
 
 
 
 
Title 
 
Purpose  
Objective, 
Hypotheses or 
Study Questions 
Population 
Sample 
Inclusion / Exclusion 
Criteria 
Interventions/ 
Variables 
Measurements 
 
Design/ 
Level of 
Evidence 
 Findings/ 
Limitations 
Article 13 
 
MacMullen, N. J., 
Dulski, L. A., & 
Blobaum, P. (2014). 
Evidence-Based 
Interventions For 
Neonatal Abstinence 
Syndrome. Pediatric 
Nursing, 165-172. 
  
 
To identify best nursing 
practice by 
systematically and 
critically reviewing the 
literature regarding 
interventions in 
Neonatal Abstinence 
Syndrome 
Population 
Characterization: 
Neonates with NAS 
 
Inclusion criteria:  
Infants with prenatal NAS 
 
Exclusion criteria: 
Infants with postnatal 
NAS 
 
 
 
IV:  
Drug classes: 
 Opiates 
 Cocaine 
 Benzodiazepines 
 Cannabis/marijuana 
 Alcohol 
 SSRIs 
DV: 
Neonatal symptoms of NAS 
Instruments: 
 
Study Design: 
Descriptive/ 
Systematic 
Review 
 
Level of 
Evidence: 
V 
Findings: 
Upon clamping of 
the cord at 
delivery, the 
transport of the 
drug is 
discontinued 
leading to the onset 
of a withdrawal 
syndrome in the 
neonate. 
Traditional 
supportive 
interventions have 
evidence for their 
use.  
 
Limitations: 
Future research of 
NAS should be at a 
higher level of 
evidence.  
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Title 
 
Purpose  
Objective, 
Hypotheses or 
Study Questions 
Population 
Sample 
Inclusion / Exclusion 
Criteria 
Interventions/ 
Variables 
Measurements 
 
Design/ 
Level of 
Evidence 
 Findings/ 
Limitations 
Article 14 
 
Maguire, D., Cline, G. J., 
Parnell, L., & Tai, C.-Y. 
(2013). Validation of the 
Finnegan Neonatal 
Abstinence Syndrome Tool-
Short Form. Advances in 
Neonatal Care, 430-437. 
   
 
To reduce items in the 
Modified Finnegan 
Scoring Tool-Short 
Form to the minimum 
possible to retain 
validity in a shorter 
version. 
Population 
Characterization: 
Infants diagnosed with 
NAS admitted to a specific 
NICU during designated 
time period. 
 
Sample Size: 
N=171 
(Males-92, Females-79) 
 
Inclusion criteria:  
All infants admitted with a 
diagnosis of NAS during 
specified time period. 
 
 
 
 
 
 
IV:  
NAS Symptoms: 
 CNS 
Disturbances 
 MVR 
Disturbances 
 GI 
Disturbances 
 
DV: 
Scores obtained using 
the M-FNAST 
 
Instruments: 
Modified Finnegan 
Neonatal Abstinence 
Syndrome Tool 
(M-FNAST) 
Study Design: 
Correlational/ 
Psychometric 
 
Level of 
Evidence: 
IV 
 
Findings: 
An emerging rise in the 
incidence of newborns 
with a passive addiction 
to heroin was observed 
in 1974, and Finnegan 
and MacNew identified a 
need for specific 
assessment and 
management of the 
condition. The M-
FNAST scores ranged 
from 0-29 with a mean 
of 3.5 (SD=2.5).  
Utilizing the short form 
when assessing NAS 
symptoms is reliable.  
 
Limitations: 
Further analysis on a 
larger scale with diverse 
populations in multiple 
settings will increase 
validity. 
 
 
 
 
Title 
 
Purpose  
Objective, 
Hypotheses or 
Study Questions 
Population 
Sample 
Inclusion / 
Exclusion Criteria 
Interventions/ 
Variables 
Measurements 
 
Design/ 
Level of 
Evidence 
 Findings/ 
Limitations 
Article 15 To evaluate the Population IV:  Study Design: Findings: 
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Murphy-Oikonen, J., 
Montelpare, W. J., Bertoldo, 
L., Southon, S., & Persichino, 
N. (2012). The impact of a 
clinical practice guideline on 
infants with neonatal 
abstinence syndrome. British 
Journal of Midwifery, 493-
501. 
  
 
effectiveness of 
clinical practice 
guidelines (CPGs) 
when managing 
neonates diagnosed 
with NAS. 
Characterization: 
Infants diagnosed 
NAS following 
exposure to opiates 
in-utero. 
 
Sample: 
N=90 
(20 pre-intervention, 
70 post-intervention) 
 
Inclusion criteria:  
Infants with two 
documented Finnegan 
NAS scores with 
symptoms of NAS. 
 
 
 
 
 
 
 
 
NAS Symptoms: 
 CNS 
Disturbances 
 MVR 
Disturbances 
 GI 
Disturbances 
 
DV: 
NAS Scores 
 
Instruments: 
 Finnegan 
Scoring Tool 
 Clinical 
Practice 
Guidelines 
(Toxicology Screening, 
Pharmacologic and 
weaning protocols) 
Retrospective/ 
cohort 
 
Level of 
Evidence: 
IV 
 
CPGs successfully benefit 
management of infants 
with NAS. Future research 
is needed to assess the 
impact of specific 
substances and interaction 
of various substances on 
neonatal withdrawal. This 
high-risk population may 
fail to attend regular 
gynecologic appointments 
or obtain prenatal care due 
to fears related to 
substance abuse revelation, 
resulting in possible 
punitive action including 
loss of child custody. 
 
Limitations: 
 Includes the 
inability to 
identify neonates 
exposed only to 
methadone.  
 Concern related 
to the  impact of 
smoking/nicotine 
withdrawal on the 
neonate. 
 
 
Title 
 
Purpose  
Objective, 
Hypotheses or 
Study Questions 
Population 
Sample 
Inclusion / 
Exclusion Criteria 
Interventions/ 
Variables 
Measurements 
 
Design/ 
Level of 
Evidence 
 Findings/ 
Limitations 
Article 16 
 
Nelson, M. (2013). Neonatal 
To address the 
nurse’s role in 
assessing withdrawal 
Population 
Characterization: 
Nurses that care for 
IV:  
Nursing Interventions 
to decrease symptoms 
Study Design: 
Descriptive 
 
Findings: 
Collaboration is needed for 
prevention of NAS and 
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Abstinence Syndrome: The 
Nurses Role. International 
Journal of Childbirth 
Education, 42. 
 
symptoms that can be 
evidenced at varying 
degrees in drug-
dependent neonates. 
infants diagnosed with 
NAS 
 
Inclusion criteria:  
Nurses that care for 
infants with symptoms 
of NAS. 
 
 
 
 
 
 
 
of NAS. 
 
DV: 
Improvement in 
symptoms of NAS in 
neonate. 
NAS Symptoms: 
 CNS 
Disturbances 
 MVR 
Disturbances 
 GI 
Disturbances 
Level of 
Evidence: 
VI 
involves prevention and 
care for the mother and the 
child. Signs of a substance 
use disorder in a pregnant 
woman include seeking 
prenatal care late in 
pregnancy, poor adherence 
to appointments, poor 
weight gain, symptoms of 
sedation, intoxication, 
withdrawal, or erratic 
behavior. 
 
Limitations: 
Lack of quality nursing 
literature on NAS. 
 
 
Title 
 
Purpose  
Objective, 
Hypotheses or Study 
Questions 
Population 
Sample 
Inclusion / Exclusion 
Criteria 
Interventions/ 
Variables 
Measurements 
 
Design/ 
Level of 
Evidence 
 Findings/ 
Limitations 
Article 17 
 
Newman, K. (2014). The 
Right Tool at the Right 
Time. Advances in Neonatal 
Care, 181-186. 
 
To identify the superior 
tool used to guide 
identification, 
assessment, and 
treatment of NAS. 
Population 
Characterization: 
Tools used to measure 
symptoms in infants 
diagnosed with NAS. 
 
 
 
 
 
 
Instruments: 
 Finnegan Scale 
 Lipsitz Tool 
 Neonatal 
Withdrawal 
Inventory 
 Sophia 
Benzodiazepine 
and Opioid 
Withdrawal 
Checklist 
 Withdrawal 
Assessment 
Tool 
  
Study Design: 
Systematic Review  
 
Level of Evidence: 
V 
Findings: 
The transient 
withdrawal 
associated with 
maternal drug use 
could have long-
term 
neurodevelopmental 
effects on the 
neonate. A 
consistent approach 
to the identification 
and assessment of 
infants with NAS is 
critical. The 
American Academy 
NAS                      38                                         
 
of Pediatrics 
recommends the 
modified Finnegan 
and the author 
suggest it be tested 
over time. Maternal 
use of opioids may 
cause neonatal 
withdrawal or acute 
toxicity that may 
lead to long-term 
neurodevelopmental 
effects. Intrauterine 
exposure to opioids 
causes symptoms of 
withdrawal in 55 to 
94 percent of 
infants.  
 
 
Title 
 
Purpose  
Objective, 
Hypotheses or Study 
Questions 
Population 
Sample 
Inclusion / 
Exclusion Criteria 
Interventions/ 
Variables 
Measurements 
 
Design/ 
Level of 
Evidence 
 Findings/ 
Limitations 
Article 18 
 
Ordean, A., & Chisamore, 
B. C. (2014). Clinical 
presentation and 
management of neonatal 
abstinence syndrome: an 
update. Research and 
Reports in Neonatology, 
75-86. 
 
To provide an evidence-
based clinical review of 
the presentation and 
management of NAS. 
Population 
Characterization: 
Infants with Neonatal 
Abstinence Syndrome. 
 
 
 
 
 
 
 
IV: Symptoms of NAS: 
Central Nervous 
System 
Crying, Sleep patterns, 
Moro Reflex, Tremors, 
Increased muscle tone, 
Excoriation, Myoclonic 
jerks, Generalized 
Convulsions 
Metabolic, vasomotor, 
and respiratory  
Sweating, Fever, 
Frequent yawning, 
Mottling, Nasal 
Study Design: 
Systematic Review 
 
Level of Evidence: 
V 
Findings: 
Between 2000 and 
2009, the incidence 
of NAS tripled with 
over 13,000 babies 
diagnosed with the 
condition in 2009. 
The agonist effects of 
opioids include 
supraspinal analgesia, 
sedation, euphoria, 
respiratory 
depression, and 
decreased 
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Stuffiness, Respiratory 
Rate 
Gastrointestinal 
Excessive sucking, 
Poor feeding, 
Regurgitation, 
Projectile Vomiting, 
Loose stools/Watery 
Stools 
DV: 
Appropriate recognition 
and treatment of 
symptoms. 
Instruments: 
 Finnegan 
Scoring 
 Lipsitz 
Scoring 
 
gastrointestinal 
motility.  Opioids 
inhibit the release of 
noradrenaline at 
synaptic terminals.   
Current knowledge 
gaps in assessment 
tools and 
management 
protocols exist in 
identification and 
treatment of infants 
with NAS.  
 
 
 
 
 
Title 
 
Purpose  
Objective, 
Hypotheses or Study 
Questions 
Population 
Sample 
Inclusion / 
Exclusion Criteria 
Interventions/ 
Variables 
Measurements 
 
Design/ 
Level of 
Evidence 
 Findings/ 
Limitations 
Article 19 
 
Paltrow, L. M., & Flavin, 
J. (2013). Arrests of and 
Forced Interventions on 
Pregnant Women in the 
United States, 1973-2005: 
Implications for Women's 
Legal Status and Public 
Health. Journal of Health 
Politics, Policy and Law, 
299-343. 
 
Description of arrests and 
forced interventions of 
pregnant women, the role 
of health care providers, 
the implications on 
pregnant women’s liberty 
and maternal, fetal, and 
child health.  
Population 
Characterization: 
Pregnant women with a 
history of attempted and 
actual deprivation of 
their physical liberty. 
 
Sample: 
N=413 
 
 
 
 
 
IV: 
 Socioeconomic 
factors 
 Race 
 
Study Design: 
Case Report 
 
Level of 
Evidence: 
V 
Findings: 
The substance-using 
woman is at risk for 
complications due to 
the exposure 
affecting not only her 
own health and 
wellbeing, but the 
passive exposure of 
her developing fetus 
as well. Multiple 
demographic and 
case characteristics 
are provided in 
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tables.  
Findings challenge 
the notion that forced 
interventions 
promote maternal, 
fetal and child health. 
Interventions are 
happening in every 
region of the country 
and affect women of 
all races.  
 
 
Title 
 
Purpose  
Objective, 
Hypotheses or Study 
Questions 
Population 
Sample 
Inclusion / 
Exclusion Criteria 
Interventions/ 
Variables 
Measurements 
 
Design/ 
Level of 
Evidence 
 Findings/ 
Limitations 
Article 20 
 
Patrick, S. W., Schumacher, 
R. E., Benneyworth, B. D., 
Krans, E. E., McAllister, J. 
M., & Davis, M. M. (2012). 
Neonatal Abstinence 
Syndrome and Associated 
Health Care Expenditures 
United States, 2000-2009. 
JAMA, E1-E7. 
  
 
To determine the 
national incidence of 
NAS and maternal opiate 
use and to identify trends 
in US health care 
expenditures associated 
with NAS.  
Population 
Characterization: 
Infants diagnosed 
with NAS 
 
 
 
 
 
 
Main Outcome 
Measures: 
 Incidence of 
NAS 
 Maternal 
Opiate Use 
 Related 
Hospital 
Charges 
Study Design: 
Retrospective, 
serial, cross-
sectional analysis  
 
 
Level of Evidence: 
III 
Findings: 
Between 2000 and 2009, 
a substantial increase in 
the incidence of NAS 
and maternal opiate use 
in the US was observed 
in addition to the 
hospital charges related 
to NAS. The number of 
infants born with 
symptoms of withdrawal 
related to passive drug 
exposure in-utero has 
been steadily increasing 
in the United States.  In 
2012, approximately one 
infant was born every 
hour with signs of drug 
withdrawal as a result of 
maternal opioid use 
Limitations: 
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Hospital discharge 
abstracts rely on accurate 
coding and errors of 
omission and 
commission may occur. 
Incidence and hospital 
related expenditures 
might be underestimated. 
 
 
Title 
 
Purpose  
Objective, 
Hypotheses or 
Study Questions 
Population 
Sample 
Inclusion / 
Exclusion Criteria 
Interventions/ 
Variables 
Measurements 
 
Design/ 
Level of 
Evidence 
 Findings/ 
Limitations 
Article 21 
 
Paulozzi, L. J., Mack, K. A., 
& Hockenberry, J. M. (2014, 
July 4). Vital Signs: 
Variation Among States in 
Prescribing of Opioid Pain 
Relievers and 
Benzodiazepines - United 
States, 2012. Retrieved from 
CDC: 
www.cdc.gov/mmwr/preview
/mmwrhtml/mm6326a2.htm?
s_cid=mm6326a2_w 
  
To examine variation 
among prescription 
rates of opioid pain 
relievers and 
benzodiazepines in the 
United States. 
Population 
Characterization: 
Persons consuming 
opioid pain relievers 
and benzodiazepines 
in the US in 2012.  
 
Inclusion criteria: 
Data was chosen by 
the CDC reflecting 
current information 
from 2012 databases. 
 
 
 
 
 
 
CDC Commercial 
Database-IMS Health 
Rankings by 
 State 
 Opioid Pain 
Relievers 
 Benzodiazepines 
 
Study Design: 
Retrospective 
study 
 
Level of 
Evidence: 
IV 
Findings: 
Opioid pain relievers and 
benzodiazepines are 
commonly prescribed in 
the United States. 
Overprescribing of 
opioid pain relievers can 
result in adverse health 
outcomes. Wide 
variation exists from one 
state to another in 
prescribing rates for 
these drugs. An urgent 
change in prescribing 
practices is necessary. 
 
 
Title 
 
Purpose  
Objective, Hypotheses 
Population 
Sample 
Interventions/ 
Variables 
Design/ 
Level of 
 Findings/ 
Limitations 
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or Study Questions Inclusion / 
Exclusion Criteria 
Measurements 
 
Evidence 
Article 22 
 
Pritham, U. (2013). 
Breastfeeding Promotion 
for Management of 
Neonatal Abstinence 
Syndrome. Journal of 
Obstetric, Gynecologic. 
and Neonatal Nursing, 
517-526. 
 
To educate perinatal 
clinicians through a review 
literature regarding the 
association between 
breastfeeding and NAS 
severity, the need for 
pharmacologic treatment of 
NAS, and length of 
hospital stay with in-utero 
exposure to methadone or 
buprenorphine opioid 
replacement therapy. 
Population 
Characterization: 
Breastfed, opiate-
exposed infants with 
NAS 
 
Inclusion criteria: 
Literature was chosen 
that included studies 
written in English on 
the topic of 
breastfeeding for 
management of NAS. 
IV:  
In-utero exposure to 
opioids 
Breastfeeding 
Opioid Maintenance 
Therapy 
Maternal contact 
 Skin-to-skin 
contact 
 Swaddling 
 Rooming in 
 
DV: 
NAS Symptoms 
Length of Hospital Stay 
 
 
Study Design: 
Systematic 
Review 
 
Level of 
Evidence: 
V 
 
Findings: 
Maternal treatment for 
opioid abuse during 
pregnancy has 
demonstrated improved 
prenatal care and 
participation adherence in 
substance abuse 
counseling. Breastfeeding 
for infants with opiate 
exposure in-utero is 
beneficial for maternal 
and infant health. 
The severity and duration 
of NAS symptoms are 
decreased. Length of stay 
is shortened when 
compared to formula 
feeding. The overall 
length of hospital stay is 
dependent on the 
successful weaning of the 
infant from the opiate.  
 
Limitations: 
Breastfeeding rates are 
low in this high-risk 
population of women and 
many stop breastfeeding 
within one week. 
 
Title 
 
Purpose  
Objective, 
Hypotheses or Study 
Questions 
Population 
Sample 
Inclusion / 
Exclusion Criteria 
Interventions/ 
Variables 
Measurements 
 
Design/ 
Level of 
Evidence 
 Findings/ 
Limitations 
Article 23 To provide intervention Population IV:  Study Design: Findings: 
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Ramakrishnan, M. (2014, 
August). Neonatal 
Abstinence Syndrome: How 
States Can Help Advance 
the Knowledge Base for 
Primary Prevention and 
Best Practices of Care. 
Retrieved from ASTHO: 
http://www.astho.org/Preve
ntion/NAS-Neonatal-
Abstinence-Report/ 
 
strategies through state 
health agencies to 
prevent prenatal 
substance exposure and 
ameliorate the impacts of 
substance-exposure in 
infancy 
Characterization: 
Substance using 
pregnant women in the 
United States and their 
exposed neonates 
diagnosed with NAS. 
 
 
 
 
 
Substance Abuse in 
pregnancy 
 
DV: 
Incidence of infants 
diagnosed with NAS 
 
Instruments: 
Data obtained through 
Department of Health, 
Policy, Planning and 
Assessment 
Birth Statistical and 
Hospital Discharge 
Data Systems 
 
Clinical 
Guidelines/ 
Program 
Evaluation 
 
Level of 
Evidence: 
V 
State-levels of intervention 
are suggested: 
 Surveillance for 
NAS-affected 
infants and 
sources of 
maternal opiate 
use 
 Early screening 
for substance 
abuse in 
pregnancy 
 Follow-up care 
for opioid-
dependent women 
 Clinical standards 
for identification, 
management, and 
follow-up of 
NAS-affected 
infants/families. 
 
 
 
Title 
 
Purpose  
Objective, 
Hypotheses or Study 
Questions 
Population 
Sample 
Inclusion / 
Exclusion Criteria 
Interventions/ 
Variables 
Measurements 
 
Design/ 
Level of 
Evidence 
 Findings/ 
Limitations 
Article 24 
 
Roy, C. (2011), Research 
Based on the Roy 
Adaptation Model: Last 25 
Years. Nursing Science  
 Quarterly, pp 312-
320. 
 
To present an overview 
of Roy Adaptation 
Model (RAM) based 
research. 
Theory/Subject: 
Roy’s Adaptation 
Model 
 
Inclusion: 
Research based on 
RAM 
 
 
 
Variables include major 
theoretical concepts of 
Roy’s Adaptation 
Model.  
 
Instrument: 
CAPS- Coping and 
Adaptation Processing 
Scale 
 47 item Likert 
Study Design: 
Descriptive 
Study 
 
Level of 
Evidence: 
V 
 
Findings: 
The categories physiologic, 
self-concept, role function, 
and interdependence have 
remained useful for 
education, practice, and 
research. 
Coping is recognized as a 
critical variable in 
understanding the effect of 
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CAPS Scale 
interpreted 
with 
psychometric 
analysis 
stress on physical and 
mental health. 
The middle-range theory of 
coping and adaptation 
processing is defined in 
detail. 
 
 
 
 
Title 
 
Purpose  
Objective, 
Hypotheses or Study 
Questions 
Population 
Sample 
Inclusion / 
Exclusion Criteria 
Interventions/ 
Variables 
Measurements 
 
Design/ 
Level of 
Evidence 
 Findings/ 
Limitations 
Article 25 
 
(2013). TennCare. 
Nashville: State of 
Tennessee. Retrieved from 
State of Tennessee: 
http://health.tn.gov/MCH/
NAS/ 
 
To provide data from the 
state of Tennessee 
regarding incidence of 
NAS among TennCare 
enrollees, demographic 
characteristics of NAS 
others, impact of NAS on 
health care expenditures, 
and percentage of 
newborns in DCS 
custody, narcotic 
prescriptions for NAS 
mothers, and 
contraceptive use among 
all women in CY 2012. 
Population 
Characterization: 
TennCare recipients 
 
Inclusion criteria: 
Enrollees on TennCare 
with diagnosis of 
NAS, mothers of NAS 
infants 
 
Exclusion criteria: 
Privately insured, out-
of-state Medicaid 
coverage, non-NAS 
infants/mothers 
 
 
 
 
 
IV:  
NAS diagnosis 
TennCare status 
 At time of 
delivery 
 Year prior to 
birth 
 Paid narcotic 
prescriptions 
 Newborns in 
DCS custody 
 Contraceptive 
use 
DV: 
Incidence 
Cost 
Instruments: 
ICD-9 Coding records 
TennCare Interchange 
Records (using social 
security numbers) 
Study Design: 
Descriptive/ 
Report of 
Program 
Evaluation 
 
Level of 
Evidence: 
VI 
Findings: 
The incidence of NAS 
among TennCare 
recipients has risen in the 
state of Tennessee of 
39.4% in 2012. The 
majority of cases are in 
east TN; 76%. 
Demographic data are 
reflected in several charts 
and graphs. Percentage of 
newborns in DCS custody 
within one year of birth is 
24.3%. Women with NAS 
babies who received 
narcotics aid for by 
TennCare appeared to be 
receiving treatment for 
dependence/addiction.   
Limitations: 
Mother’s receiving 
methadone treatment 
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would not be covered by 
TennCare therefore those 
services were not reflected 
in this study. 
 
Title 
 
Purpose  
Objective, 
Hypotheses or Study 
Questions 
Population 
Sample 
Inclusion / 
Exclusion Criteria 
Interventions/ 
Variables 
Measurements 
 
Design/ 
Level of 
Evidence 
 Findings/ 
Limitations 
Article 26 
 
Warren, M. (2013). 
Tennessee Efforts to Prevent 
Neonatal Abstinence 
Syndrome. Retrieved from 
State of Tennessee: 
http://www.tn.gov/tccy/pres
-CAD-13-NAS.pdf 
 
 To review the 
etiology, 
diagnosis, and 
treatment of 
NAS. 
 To describe 
scope of NAS in 
Tennessee and 
US 
 To share TN 
efforts related to 
NAS prevention. 
Population 
Characterization: 
Neonates with history 
of intrauterine opioid 
exposure. 
 
Inclusion criteria:  
Neonates with history 
of intrauterine opioid 
exposure in the state of 
Tennessee. 
 
Exclusion criteria: 
Infants without history 
of intrauterine 
exposure. 
Infants born outside of 
the state of Tennessee. 
 
 
 
 
IV:  
History of maternal 
opiate use during 
pregnancy 
Specific substance 
abused 
CNS symptoms 
GI symptoms 
Social/environmental 
issues 
 
DV: 
Short and long-term 
consequences of 
NAS 
 
Instruments: 
 
Study Design: 
Descriptive/ 
Systematic Review 
 
Level of Evidence: 
V 
 
Findings: 
No definitive log-term 
consequences of NAS. 
Social/environmental 
variables may 
confound outcomes. 
Incidence of NAS has 
increased 2.8-fold in 
the US. Hospital costs 
are high with 78% of 
charges to state 
Medicaid programs. 
Incidence has sharply 
increased in Tennessee 
with highest incidence 
in East TN with nearly 
all covered by 
TennCare. Prevention 
efforts have been 
initiated to help 
control epidemic. 
 
 
 
 
